Melinda L. Telli
YOU?
Author Swipe
View article: Figure S3 from A Four Amino Acid Intracellular Motif of VISTA Blocks Growth Receptor Signaling in Cancer Cells to Induce Tumor Suppression
Figure S3 from A Four Amino Acid Intracellular Motif of VISTA Blocks Growth Receptor Signaling in Cancer Cells to Induce Tumor Suppression Open
Figure S3
View article: Figure S6 from A Four Amino Acid Intracellular Motif of VISTA Blocks Growth Receptor Signaling in Cancer Cells to Induce Tumor Suppression
Figure S6 from A Four Amino Acid Intracellular Motif of VISTA Blocks Growth Receptor Signaling in Cancer Cells to Induce Tumor Suppression Open
Figure S6
View article: Data from A Four Amino Acid Intracellular Motif of VISTA Blocks Growth Receptor Signaling in Cancer Cells to Induce Tumor Suppression
Data from A Four Amino Acid Intracellular Motif of VISTA Blocks Growth Receptor Signaling in Cancer Cells to Induce Tumor Suppression Open
V-domain immunoglobulin suppressor of T-cell activation (VISTA, VSIR) is a key immune checkpoint receptor under investigation as a target for cancer immunotherapy. However, a better understanding of the signaling mechanisms of VISTA…
View article: Figure S4 from A Four Amino Acid Intracellular Motif of VISTA Blocks Growth Receptor Signaling in Cancer Cells to Induce Tumor Suppression
Figure S4 from A Four Amino Acid Intracellular Motif of VISTA Blocks Growth Receptor Signaling in Cancer Cells to Induce Tumor Suppression Open
Figure S4
View article: Figure S5 from A Four Amino Acid Intracellular Motif of VISTA Blocks Growth Receptor Signaling in Cancer Cells to Induce Tumor Suppression
Figure S5 from A Four Amino Acid Intracellular Motif of VISTA Blocks Growth Receptor Signaling in Cancer Cells to Induce Tumor Suppression Open
Figure S5
View article: Figure S2 from A Four Amino Acid Intracellular Motif of VISTA Blocks Growth Receptor Signaling in Cancer Cells to Induce Tumor Suppression
Figure S2 from A Four Amino Acid Intracellular Motif of VISTA Blocks Growth Receptor Signaling in Cancer Cells to Induce Tumor Suppression Open
Figure S2
View article: Figure S1 from A Four Amino Acid Intracellular Motif of VISTA Blocks Growth Receptor Signaling in Cancer Cells to Induce Tumor Suppression
Figure S1 from A Four Amino Acid Intracellular Motif of VISTA Blocks Growth Receptor Signaling in Cancer Cells to Induce Tumor Suppression Open
Figure S1
View article: Etirinotecan Pegol (<scp>NKTR</scp>‐102) in Patients With Active Brain Metastases From Lung or Breast Cancer
Etirinotecan Pegol (<span>NKTR</span>‐102) in Patients With Active Brain Metastases From Lung or Breast Cancer Open
Background Brain metastases are common in patients with lung and breast cancer and are associated with poor outcomes. While there is some intracranial activity with systemic therapies, most chemotherapies are minimally effective. Etirinote…
View article: A 20-feature radiomic signature of triple-negative breast cancer identifies patients at high risk of death
A 20-feature radiomic signature of triple-negative breast cancer identifies patients at high risk of death Open
View article: A Four Amino Acid Intracellular Motif of VISTA Blocks Growth Receptor Signaling in Cancer Cells to Induce Tumor Suppression
A Four Amino Acid Intracellular Motif of VISTA Blocks Growth Receptor Signaling in Cancer Cells to Induce Tumor Suppression Open
V-domain immunoglobulin suppressor of T-cell activation (VISTA, VSIR) is a key immune checkpoint receptor under investigation as a target for cancer immunotherapy. However, a better understanding of the signaling mechanisms of VISTA is nee…
View article: Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial
Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial Open
View article: Impact of Timing of Diagnosis and Breastfeeding on Postpartum Breast Cancer Outcomes
Impact of Timing of Diagnosis and Breastfeeding on Postpartum Breast Cancer Outcomes Open
Purpose Postpartum breast cancers (PPBC) have a worse prognosis than other breast cancers, but the impact of timing postpartum (PP) and concurrent breastfeeding (BF) remains unclear. Methods We analyzed 161 PPBC patients diagnosed from 200…
View article: A 20-feature radiomic signature of triple-negative breast cancer identifies patients at high risk of death
A 20-feature radiomic signature of triple-negative breast cancer identifies patients at high risk of death Open
A substantial proportion of patients with non-metastatic triple-negative breast cancer (TNBC) experience disease progression and death despite treatment. However, no tool currently exists to discriminate those at higher risk of death. To i…
View article: Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2− breast cancer: a randomized phase 3 trial
Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2− breast cancer: a randomized phase 3 trial Open
Addition of pembrolizumab to neoadjuvant chemotherapy followed by adjuvant pembrolizumab improved outcomes in patients with high-risk, early-stage, triple-negative breast cancer. However, whether the addition of neoadjuvant pembrolizumab t…
View article: VISTA-induced tumor suppression by a four amino acid intracellular motif
VISTA-induced tumor suppression by a four amino acid intracellular motif Open
Summary VISTA is a key immune checkpoint receptor under investigation for cancer immunotherapy; however, its signaling mechanisms remain unclear. Here we identify a conserved four amino acid (NPGF) intracellular motif in VISTA that suppres…
View article: 92 High-dimensional, single-cell analysis and transcriptional profiling reveal novel correlatives of response to PARP inhibition plus PD-1 blockade in triple-negative breast cancer
92 High-dimensional, single-cell analysis and transcriptional profiling reveal novel correlatives of response to PARP inhibition plus PD-1 blockade in triple-negative breast cancer Open
View article: Supplementary Data from A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors
Supplementary Data from A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors Open
Figures S1-S3 and Supplementary Methods
View article: Data from A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors
Data from A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors Open
Purpose:Glutamine is a critical fuel for solid tumors. Interference with glutamine metabolism is deleterious to neoplasia in preclinical models. A phase I study of the oral, first-in-class, glutaminase (GLS) inhibitor telaglenastat was con…
View article: Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status
Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status Open
View article: 264TiP TACTIVE-K: Phase Ib/II study of vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in combination with PF-07220060, a cyclin-dependent kinase (CDK)4 inhibitor, in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer
264TiP TACTIVE-K: Phase Ib/II study of vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in combination with PF-07220060, a cyclin-dependent kinase (CDK)4 inhibitor, in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer Open
Vepdegestrant (ARV-471) is an investigational, orally administered PROTAC ER degrader. Initial results from a phase Ib cohort of a first-in-human phase I/II study (NCT04072952) showed that vepdegestrant, in combination with the CDK4/6 inhi…
View article: 218P Vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, plus palbociclib (palbo) in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Updated phase Ib cohort results
218P Vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, plus palbociclib (palbo) in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Updated phase Ib cohort results Open
Preliminary phase Ib cohort results from a phase 1/2 study (NCT04072952) evaluating vepdegestrant (ARV-471) plus palbo showed promising clinical activity in heavily pretreated patients (pts) with ER+/HER2- advanced breast cancer (data cuto…
View article: Tumor-infiltrating lymphocytes and breast cancer mortality in racially and ethnically diverse participants of the Northern California Breast Cancer Family Registry
Tumor-infiltrating lymphocytes and breast cancer mortality in racially and ethnically diverse participants of the Northern California Breast Cancer Family Registry Open
Stromal tumor-infiltrating lymphocyte (sTIL) enrichment in pretreatment breast tumors has been associated with superior response to neoadjuvant treatment and survival. In a population-based cohort, we studied sTIL-survival associations by …
View article: Building Efficiency and Scaling With a Remote Genetic Counseling Program
Building Efficiency and Scaling With a Remote Genetic Counseling Program Open
Purpose A third-party telemedicine (TM) genetic counseling program was initiated at a large community oncology practice spanning 35 clinical sites with 110 clinicians and 97 advanced practice providers throughout Tennessee and Georgia. Pat…
View article: Generation and characterization of induced pluripotent stem cells from breast cancer patients carrying ATM mutations
Generation and characterization of induced pluripotent stem cells from breast cancer patients carrying ATM mutations Open
View article: Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study
Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study Open
View article: Generation of two induced pluripotent stem cell lines from breast cancer patients carrying BRCA2 variants
Generation of two induced pluripotent stem cell lines from breast cancer patients carrying BRCA2 variants Open
View article: LBA21 KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2– breast cancer
LBA21 KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2– breast cancer Open
View article: Response to trastuzumab deruxtecan in a patient with HER2-low metastatic breast cancer previously treated with sacituzumab govitecan
Response to trastuzumab deruxtecan in a patient with HER2-low metastatic breast cancer previously treated with sacituzumab govitecan Open
The treatment landscape for metastatic triple negative breast cancer has shifted dramatically in the last few years with the introduction of PARP inhibitors, immunotherapy, and antibody drug conjugates. The two antibody drug conjugates, sa…
View article: Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes
Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes Open
View article: Neoadjuvant Talazoparib in Patients With Germline <i>BRCA1/2</i> Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study
Neoadjuvant Talazoparib in Patients With Germline <i>BRCA1/2</i> Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study Open
Background The undetermined efficacy of the current standard-of-care neoadjuvant treatment, anthracycline/platinum-based chemotherapy, in patients with early-stage triple-negative breast cancer (TNBC) and germline BRCA mutations emphasizes…